NZ602055A - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases - Google Patents
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesInfo
- Publication number
- NZ602055A NZ602055A NZ602055A NZ60205511A NZ602055A NZ 602055 A NZ602055 A NZ 602055A NZ 602055 A NZ602055 A NZ 602055A NZ 60205511 A NZ60205511 A NZ 60205511A NZ 602055 A NZ602055 A NZ 602055A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- treatment
- apoptosis
- immune
- myeloma
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000003445 Mouth Neoplasms Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000000277 Splenic Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000006491 bone marrow cancer Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000003444 follicular lymphoma Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 230000000527 lymphocytic effect Effects 0.000 abstract 1
- 208000003747 lymphoid leukemia Diseases 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- SUZXWXGJCOCMHU-UHFFFAOYSA-N n-sulfonylbenzamide Chemical class O=S(=O)=NC(=O)C1=CC=CC=C1 SUZXWXGJCOCMHU-UHFFFAOYSA-N 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002471 spleen cancer Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ628298A NZ628298A (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31757510P | 2010-03-25 | 2010-03-25 | |
| PCT/US2011/027895 WO2011119345A2 (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602055A true NZ602055A (en) | 2014-08-29 |
Family
ID=43858249
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602055A NZ602055A (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ628298A NZ628298A (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628298A NZ628298A (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8188077B2 (enExample) |
| EP (3) | EP2957558A3 (enExample) |
| JP (1) | JP5959501B2 (enExample) |
| KR (1) | KR20130040834A (enExample) |
| CN (2) | CN102947283B (enExample) |
| AU (1) | AU2011229862B2 (enExample) |
| BR (1) | BR112012024382A2 (enExample) |
| CA (1) | CA2792276A1 (enExample) |
| DK (1) | DK2550258T3 (enExample) |
| ES (1) | ES2553143T3 (enExample) |
| HK (2) | HK1200444A1 (enExample) |
| HR (1) | HRP20151218T1 (enExample) |
| HU (1) | HUE026241T2 (enExample) |
| IL (2) | IL221771A (enExample) |
| MX (1) | MX2012011086A (enExample) |
| NZ (2) | NZ602055A (enExample) |
| PL (1) | PL2550258T3 (enExample) |
| PT (1) | PT2550258E (enExample) |
| RS (1) | RS54388B1 (enExample) |
| RU (2) | RU2568611C2 (enExample) |
| SG (2) | SG184094A1 (enExample) |
| SI (1) | SI2550258T1 (enExample) |
| SM (1) | SMT201600016B (enExample) |
| TW (2) | TWI535713B (enExample) |
| WO (1) | WO2011119345A2 (enExample) |
| ZA (1) | ZA201206837B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| BRPI1006116A2 (pt) | 2009-01-19 | 2018-03-13 | Abbott Lab | "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes". |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| EP2790725A4 (en) | 2011-12-13 | 2015-11-04 | Buck Inst For Res On Aging | METHODS FOR IMPROVING MEDICAL THERAPIES |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| PE20150400A1 (es) | 2012-05-22 | 2015-03-27 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor |
| ES2595240T3 (es) | 2012-07-09 | 2016-12-28 | Lupin Limited | Derivados de tetrahidroquinazolinona como inhibidores de PARP |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| CN110623956A (zh) | 2014-01-28 | 2019-12-31 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| KR101643280B1 (ko) * | 2014-09-02 | 2016-07-28 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피페리딘카복사마이드 유도체 및 이의 의학적 용도 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| ES2939609T3 (es) * | 2015-11-27 | 2023-04-25 | Taiho Pharmaceutical Co Ltd | Compuesto de bifenilo o sal del mismo |
| KR102359439B1 (ko) * | 2017-03-31 | 2022-02-09 | (주)아모레퍼시픽 | 벤조산아마이드 화합물 및 사이클로덱스트린 용해보조제를 포함하는 조성물 |
| US11510915B2 (en) * | 2017-05-26 | 2022-11-29 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor effect potentiator using novel biphenyl compound |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| CN117430601A (zh) | 2018-04-29 | 2024-01-23 | 百济神州有限公司 | Bcl-2抑制剂 |
| RU2693378C1 (ru) * | 2018-10-02 | 2019-07-02 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Фармацевтическая композиция, проявляющая цитотоксическое действие в отношении клеток рака мочевого пузыря человека |
| SG11202113092WA (en) * | 2019-06-10 | 2021-12-30 | Adc Therapeutics Sa | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent |
| EP4051676A4 (en) | 2019-10-28 | 2023-11-22 | BeiGene, Ltd. | BCL-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| CN116802179A (zh) | 2020-04-15 | 2023-09-22 | 百济神州有限公司 | Bcl-2抑制剂 |
| WO2022161496A1 (en) * | 2021-02-01 | 2022-08-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Sulfonyl benzamide derivatives as bcl-2 inhibitors |
| CN117642157A (zh) | 2021-03-19 | 2024-03-01 | 伊尔治疗学股份有限公司 | 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物 |
| WO2024032776A1 (en) * | 2022-08-12 | 2024-02-15 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5892655A (ja) * | 1981-11-27 | 1983-06-02 | Otsuka Chem Co Ltd | カ−バメイト系誘導体、その製造方法及びその誘導体を有効成分として含有する殺虫剤 |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| DE69631347T2 (de) | 1995-09-15 | 2004-10-07 | Upjohn Co | Aminoaryl oxazolidinone n-oxide |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| AR031130A1 (es) * | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US20050049594A1 (en) * | 2001-04-20 | 2005-03-03 | Wack Michael A. | Dual locking plate and associated method |
| EP1401806B1 (en) * | 2001-06-06 | 2006-08-09 | Eli Lilly And Company | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| AU4235802A (en) * | 2002-05-20 | 2003-11-27 | Andreas Krumbacher | Combinations flexible apparatus (multiple flexibletrack) |
| US7282595B2 (en) * | 2002-11-22 | 2007-10-16 | Eli Lilly And Company | Antitumor benzoylsulfonamides |
| WO2005024636A1 (ja) | 2003-09-04 | 2005-03-17 | Hitachi Ulsi Systems Co., Ltd. | 半導体装置 |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
| ATE542796T1 (de) * | 2004-05-26 | 2012-02-15 | Abbott Lab | N-sulfonylcarboximidamidverbindungen als apoptosepromotoren |
| PL1768967T3 (pl) | 2004-07-20 | 2009-09-30 | Symed Labs Ltd | Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| US20060088886A1 (en) * | 2004-10-25 | 2006-04-27 | Anlong Ouyang | Topiramate analogs |
| TWI337182B (en) * | 2005-05-12 | 2011-02-11 | Abbott Lab | Apoptosis promoters |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| JP5130305B2 (ja) | 2007-02-15 | 2013-01-30 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしての２−アミノオキサゾリン |
| JP2010524972A (ja) | 2007-04-19 | 2010-07-22 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化したモルホリニル化合物 |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009036035A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090137457A1 (en) | 2007-10-02 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| NZ601350A (en) * | 2007-11-16 | 2013-08-30 | Abbvie Inc | Method of treating arthritis |
| US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) * | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| BRPI1006116A2 (pt) * | 2009-01-19 | 2018-03-13 | Abbott Lab | "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes". |
| JP5613177B2 (ja) * | 2009-01-19 | 2014-10-22 | アッヴィ・インコーポレイテッド | 癌並びに免疫及び自己免疫疾患の治療用アポトーシス誘導剤 |
-
2011
- 2011-03-10 HR HRP20151218TT patent/HRP20151218T1/hr unknown
- 2011-03-10 CN CN201180015915.4A patent/CN102947283B/zh not_active Expired - Fee Related
- 2011-03-10 KR KR1020127027672A patent/KR20130040834A/ko not_active Ceased
- 2011-03-10 NZ NZ602055A patent/NZ602055A/en not_active IP Right Cessation
- 2011-03-10 WO PCT/US2011/027895 patent/WO2011119345A2/en not_active Ceased
- 2011-03-10 MX MX2012011086A patent/MX2012011086A/es active IP Right Grant
- 2011-03-10 BR BR112012024382A patent/BR112012024382A2/pt not_active IP Right Cessation
- 2011-03-10 RS RS20150756A patent/RS54388B1/sr unknown
- 2011-03-10 RU RU2012145298/04A patent/RU2568611C2/ru not_active IP Right Cessation
- 2011-03-10 AU AU2011229862A patent/AU2011229862B2/en not_active Ceased
- 2011-03-10 JP JP2013501293A patent/JP5959501B2/ja not_active Expired - Fee Related
- 2011-03-10 CN CN201510587254.2A patent/CN105218483A/zh active Pending
- 2011-03-10 EP EP15178279.4A patent/EP2957558A3/en not_active Withdrawn
- 2011-03-10 SG SG2012068615A patent/SG184094A1/en unknown
- 2011-03-10 NZ NZ628298A patent/NZ628298A/en not_active IP Right Cessation
- 2011-03-10 SG SG10201406608YA patent/SG10201406608YA/en unknown
- 2011-03-10 PL PL11709579T patent/PL2550258T3/pl unknown
- 2011-03-10 EP EP11709579.4A patent/EP2550258B1/en active Active
- 2011-03-10 PT PT117095794T patent/PT2550258E/pt unknown
- 2011-03-10 CA CA2792276A patent/CA2792276A1/en not_active Abandoned
- 2011-03-10 RU RU2015141713A patent/RU2015141713A/ru unknown
- 2011-03-10 SI SI201130660T patent/SI2550258T1/sl unknown
- 2011-03-10 HU HUE11709579A patent/HUE026241T2/en unknown
- 2011-03-10 ES ES11709579.4T patent/ES2553143T3/es active Active
- 2011-03-10 DK DK11709579.4T patent/DK2550258T3/en active
- 2011-03-10 EP EP14160660.8A patent/EP2757105A1/en not_active Withdrawn
- 2011-03-16 US US13/049,569 patent/US8188077B2/en not_active Expired - Fee Related
- 2011-03-25 TW TW100110483A patent/TWI535713B/zh not_active IP Right Cessation
- 2011-03-25 TW TW105106938A patent/TW201623291A/zh unknown
-
2012
- 2012-04-27 US US13/458,968 patent/US8343967B2/en not_active Expired - Fee Related
- 2012-09-04 IL IL221771A patent/IL221771A/en not_active IP Right Cessation
- 2012-09-12 ZA ZA2012/06837A patent/ZA201206837B/en unknown
-
2013
- 2013-06-06 HK HK15100726.4A patent/HK1200444A1/en unknown
-
2014
- 2014-03-25 IL IL231702A patent/IL231702A0/en unknown
-
2016
- 2016-01-15 SM SM201600016T patent/SMT201600016B/it unknown
- 2016-06-17 HK HK16107017.6A patent/HK1219092A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602055A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| NZ561609A (en) | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters | |
| NZ590334A (en) | ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF | |
| SA519401020B1 (ar) | مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2 | |
| NZ710270A (en) | Pyridone amides as modulators of sodium channels | |
| NZ630196A (en) | Cyclic amides as metap-2 inhibitors | |
| MX2010003865A (es) | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| PH12012502142A1 (en) | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| GB201212081D0 (en) | New polymorph | |
| NZ703941A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| MX2010003866A (es) | Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| NZ601422A (en) | Substituted pyrrolidine-2-carboxamides | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| IL204437A (en) | History of aryl cyclic profile and their use | |
| NZ604379A (en) | Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k | |
| MX2010009268A (es) | Compuestos que son inhibidores de erk. | |
| SG153851A1 (en) | N-(1-(1-benzyl -4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer | |
| IN2012DN03182A (enExample) | ||
| MX338551B (es) | Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. | |
| PH12015500376B1 (en) | Novel bicyclic pyridinones | |
| SG10201810357WA (en) | Ly75 as cancer therapeutic and diagnostic target | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| TN2011000456A1 (en) | Treatment of pancreatic cancer | |
| MX2012011382A (es) | Nuevo polimero. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE FILED DATE HAS BEEN CORRECTED TO 10/03/2011 Effective date: 20140818 Free format text: THE FILED DATE HAS BEEN CORRECTED TO 25/03/2010 Effective date: 20140815 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2016 BY THOMSON REUTERS Effective date: 20141221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2017 BY THOMSON REUTERS Effective date: 20160217 |
|
| LAPS | Patent lapsed |